The scientific literature on COVID-19 is rapidly evolving and these articles were selected for review based on their relevance to Washington State decision making around COVID-19 response efforts. Included in these Lit Reps are some manuscripts that have been made available online as pre-prints but have not yet undergone peer review. Please be aware of this when reviewing articles included in the Lit Reps.<\/p>\n
Today’s summary is based on a review of 540 articles (524 published, 16 in preprint)<\/em><\/p>\n View the PDF version here.<\/a><\/strong><\/p>\n \t\t\t\t<\/p>\n Hippich et al.\u00a0(Apr 3, 2021). A Public Health Antibody Screening Indicates a Marked Increase of SARS-CoV-2 Exposure Rate in Children during the Second Wave. Med. <\/span><\/i>https:\/\/doi.org\/10.1016\/j.medj.2021.03.019<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n \t\t\t\t<\/p>\n Graham et al.\u00a0(Apr 12, 2021). Changes in Symptomatology, Reinfection, and Transmissibility Associated with the SARS-CoV-2 Variant B.1.1.7: An Ecological Study. The Lancet Public Health. <\/span><\/i>https:\/\/www.thelancet.com\/journals\/lanpub\/article\/PIIS2468-2667(21)00055-4\/fulltext<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n<\/div>\n<\/div>\n \t\t\t\t<\/p>\n Yu et al.\u00a0(Apr 12, 2021). Inhaled Budesonide for COVID-19 in People at Higher Risk of Adverse Outcomes in the Community Interim Analyses from the PRINCIPLE Trial. Pre-print downloaded Apr 13 from <\/span><\/i>https:\/\/doi.org\/10.1101\/2021.04.10.21254672<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n \t\t\t\t<\/p>\n Ramakrishnan et al.\u00a0(Apr 9, 2021). Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A Phase 2, Open-Label, Randomised Controlled Trial. The Lancet Respiratory Medicine. <\/span><\/i>https:\/\/doi.org\/10.1016\/S2213-2600(21)00160-0<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n<\/div>\n<\/div>\n \t\t\t\t<\/p>\n Rabi et al.\u00a0(Apr 12, 2021). Factors Affecting Nurses\u2019 Intention to Accept the COVID-9 Vaccine: A Cross-sectional Study. Public Health Nursing. <\/span><\/i>https:\/\/doi.org\/10.1111\/phn.12907<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n \t\t\t\t<\/p>\n Perl et al.\u00a0(Apr 12, 2021). SARS-CoV-2\u2013Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. JAMA. <\/span><\/i>https:\/\/doi.org\/10.1001\/jama.2021.5782<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n \t\t\t\t<\/p>\n Papst et al.\u00a0(Dec 12, 2021). Age-Dependence of Healthcare Interventions for COVID-19 in Ontario, Canada. BMC Public Health. <\/span><\/i>https:\/\/doi.org\/10.1186\/s12889-021-10611-4<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n \t\t\t\t<\/p>\n Harrington et al.\u00a0(Mar 24, 2021). Rapid Decline of Neutralizing Antibodies Is Associated with Decay of IgM in Adults Recovered from Mild COVID-19 Disease. Cell Reports Medicine. <\/span><\/i>https:\/\/doi.org\/10.1016\/j.xcrm.2021.100253<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n \t\t\t\t<\/p>\n Hall et al.\u00a0(Apr 9, 2021). SARS-CoV-2 Infection Rates of Antibody-Positive Compared with Antibody-Negative Health-Care Workers in England: A Large, Multicentre, Prospective Cohort Study (SIREN). The Lancet. <\/span><\/i>https:\/\/doi.org\/10.1016\/S0140-6736(21)00675-9<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n<\/div>\n<\/div>\n \t\t\t\t<\/p>\n Smith et al.\u00a0(Apr 13, 2021). Hospital-Acquired Infections among Adult Patients Admitted for COVID-19. Infection Control & Hospital Epidemiology. <\/span><\/i>https:\/\/doi.org\/10.1017\/ice.2021.148<\/span><\/a><\/p>\n<\/p>\n<\/div>\n \t\t\t\t\t\t\t\t\t<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n Report prepared by the UW Alliance for Pandemic Preparedness and Global Health Security and the START Center in collaboration with and on behalf of WA DOH COVID-19 Incident Management Team<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":" Prior SARS-CoV-2 infection was associated with an 84% lower risk of infection according to the SIREN Study, a large cohort study of over 25,000 individuals. From June to December 2020, reinfections\/infections were detected in 0.02% (155 of 8,278) of participants positive at baseline compared to 0.1% (1,704 of 17,383) of participants negative at baseline. The authors found no evidence that the emergence of the B.1.1.7 variant was linked to increased reinfection rates. <\/p>\nKey Takeaways<\/h2>\n
\n
\n
\n
\n
Article Summaries<\/h3>\n
Transmission<\/span><\/h2>\n
A Public Health Antibody Screening Indicates a Marked Increase of SARS-CoV-2 Exposure Rate in Children during the Second Wave<\/h5>\n
\n
Changes in Symptomatology, Reinfection, and Transmissibility Associated with the SARS-CoV-2 Variant B.1.1.7: An Ecological Study<\/h5>\n
\n
Testing and Treatment<\/span><\/h2>\n
Inhaled Budesonide for COVID-19 in People at Higher Risk of Adverse Outcomes in the Community Interim Analyses from the PRINCIPLE Trial<\/h5>\n
\n
Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A Phase 2, Open-Label, Randomised Controlled Trial<\/h5>\n
\n
Vaccines and Immunity<\/h2>\n
Factors Affecting Nurses\u2019 Intention to Accept the COVID-9 Vaccine: A Cross-sectional Study<\/h5>\n
\n
SARS-CoV-2\u2013Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women<\/h5>\n
\n
Age-Dependence of Healthcare Interventions for COVID-19 in Ontario, Canada<\/h5>\n
\n
Rapid Decline of Neutralizing Antibodies Is Associated with Decay of IgM in Adults Recovered from Mild COVID-19 Disease<\/h5>\n
\n
SARS-CoV-2 Infection Rates of Antibody-Positive Compared with Antibody-Negative Health-Care Workers in England: A Large, Multicentre, Prospective Cohort Study (SIREN)<\/h5>\n
\n
Clinical Characteristics and Health Care Setting<\/span><\/h2>\n
Hospital-Acquired Infections among Adult Patients Admitted for COVID-19<\/h5>\n
\n
Other Resources and Commentaries<\/h2>\n
\n